Interference of Carbamazepine and Carbamazepine 10,11-Epoxide in the Flourescence Polarization Immunoassay for Tricyclic Antidepressants: Estimation of the True Tricyclic Antidepressant Concentration in the Presence of Carbamazepine Using A Mathematical Model

American Journal of Clinical Pathology

Volumn 121, Issue 3, 2004, Pages 418-425

  Dasgupta, Amitava ^a   McNeese, Catherine ^a   Wells, Alice ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Carbamazepine; Fluorescence polarization immunoassay; FPIA; Interference; Tricyclic antidepressant

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; DRUG METABOLITE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG EFFECT; DRUG MONITORING; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; PRIORITY JOURNAL;

EID: 1542377668     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/WBQ2C5FLYYHKYCT4     Document Type: Article

References (17)

1. Szymura-Olenksiak J, Waska E, Wasieczko A. Pharmacokinetic interaction between carbamazepine in patients with major depression. Psychopharmacology. 2001;154:38-42.
2. Stein G. Drug treatment of personality disorder. Br J Psychiatry. 1992;161:167-184.
3. Small JG. Anticonvulsants in affective disorders. Psychopharmacol Bull. 1990;26:25-36.
4. Sindrup SH, Jensen TS. Pharmacological treatment of pain in polyneuropathy. Neurology. 2000;55:915-920.
5. Gold MS, Pottash AL, Stoll A, et al. Nortriptyline plasma levels and clinical response in patients with familial pure unipolar depression and blunted TRH tests. Int J Psychiatry Med. 1983;13:215-220.
6. Glassman AH. Cardiovascular effects of tricyclic antidepressants. Annu Rev Med. 1984;35:503-511.
7. Warrington SJ, Padgham C, Lader M. The cardiovascular effects of antidepressants. Psychol Med Monogr Suppl. 1989;16:1-40.
8. Preskorn SH, Fast GA. Tricyclic antidepressant induced seizures and plasma drug concentrations. J Clin Psychiatry. 1992;53:160-162.
9. Preskorn SH, Dorey RC, Jekovich GS. Therapeutic drug monitoring of tricyclic antidepressants. Clin Chem. 1988;34:822-828.
10. de la Torre R, Ortuno J, Pascual JA, et al. Quantitative determination of tricyclic antidepressants and their metabolites in plasma by solid-phase extraction (Bond-Elut TCA) and separation by capillary gas chromatography with nitrogen-phosphorus detection. Ther Drug Monit. 1998;20:340-346.
11. Hackett LP, Dusci LJ, Ilett KF. A comparison of high performance liquid chromatography and fluorescence polarization immunoassay for therapeutic drug monitoring of tricyclic antidepressants. Ther Drug Monit. 1998;20:30-34.
12. Rao ML, Deister A, Laux G, et al. Low serum levels of tricyclic antidepressants in amitriptyline- and doxepin-treated inpatients with depressive syndromes are associated with nonresponse. Pharmacopsychiatry. 1996;29:97-102.
13. Radziwon-Zaleska M, Matsumoto H, Skalski M, et al. Therapeutic drug monitoring in depression. Pol J Pharmacol. 2000;52:255-266.
14. Chattergoon DS, Verjee Z, Anderson M, et al. Carbamazepine interference with an immunoassay for tricyclic antidepressants in plasma. J Toxicol Clin Toxicol. 1998;36:109-113.
15. Fleischman A, Chiang VW. Carbamazepine overdose recognized by a tricyclic antidepressant assay. Pediatrics. 2001;107:176-177.
16. Matos ME, Burns MM, Shannon MW. False-positive tricyclic antidepressant drug screen results leading to the diagnosis of carbamazepine intoxication. Pediatrics. 2000;105:E66. Available at: http://www.pediatrics.org. Accessed February 12, 2003.
17. Miller JJ, Valdes R Jr. Methods for calculating cross reactivity in immunoassays. J Clin Immunoassay. 1992;15:97-100.